Why RxSight, Inc.’s (RXST) Stock Is Up 6.56%
As of Tuesday, July 28, RxSight, Inc.’s RXST share price has surged by 6.56%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Commentary & Analysis
Why RxSight, Inc.’s (RXST) Stock Is Up 6.07%
As of Monday, July 27, RxSight, Inc.’s RXST share price has surged by 6.07%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why RxSight, Inc.’s (RXST) Stock Is Down 6.61%
As of Tuesday, July 07, RxSight, Inc.’s RXST share price has dipped by 6.61%, which has investors questioning if this is right time to buy.Jenna Brashear
3 Undervalued Health Care Equipment & Supplies Stocks for Tuesday, June 30
Discover the top 3 undervalued Health Care Equipment & Supplies stocks for Tuesday, June 30 based on AAII’s Stock Grades.Michael Rose
Why RxSight, Inc.’s (RXST) Stock Is Down 5.88%
As of Tuesday, June 30, RxSight, Inc.’s RXST share price has dipped by 5.88%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | RXST | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $252.1 | $334.8 | 30% |
|
| Shares Out (Mil) | 41.3 | 41.7 | 44% |
|
| Institutional Ownership | 94.4% | 77.3% | 65% |
|
| Float (Mil) | 39.1 | 34.7 | 42% |
|
| Beta | 1.23 | 0.86 | 72% |
|
| Avg Daily Volume (000s) | 933 | 266 | 69% |
|
| Price Change (52-week) |
(22.2%) | 60.7% | 30% |
|
| Growth | RXST | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 55.7% | 11.8% | 96% |
|
| Net Income (5yr) | (27.8%) | (5.8%) | 15% |
|
| EPS (5yr) | (52.1%) | 10.7% | 3 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (44.5%) | (16.1%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.188) | ($0.668) | ($0.673) | |
| Month Ago EPS | ($0.200) | ($0.700) | ($0.560) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.170) | ($0.645) | ($0.483) | |
| Year/Year Chg | (51.2%) | (29.9%) | (53.1%) | |
| Financials | RXST | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $128 | $152 | 29% |
|
| Net Income (TTM) (Mil) | ($47) | ($11) | 17% |
|
| EPS (TTM) | ($1.136) | ($0.500) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($18) | ($2) | 15% |
|
| Net Cash Flow (TTM) (Mil) | ($10) | $1 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $9 | $22 | 28% |
|
| Enterprise Value (Q1) (Mil) | $33 | $304 | 14% |
|
| Valuation | RXST | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.94 | 2.88 | 21% |
|
| P/E | na | 30.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | RXST | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.0% | 59.1% | 87% |
|
| Net Margin | (36.6%) | (7.7%) | 14% |
|
| ROA | (15.1%) | (13.7%) | 23% |
|
| ROE | (17.1%) | (15.9%) | 25% |
|
| Liabilities to Assets | 12.1% | 44.9% | 7% |
|
| F-Score | 3 | 4 | 19% |
|
RxSight, Inc. did not pass any screens on 7/30/2026.
